Pharma BD Deal Intelligence
Milestone-only AI co-development of a preclinical CNS asset
Full analysis, sources & comparables →China Medical System Holdings (CMS) and Insilico Medicine expanded their partnership with an additional AI-empowered drug discovery collaboration targeting a mass-market central nervous system indication with a novel mechanism of action identified by Insilico's PandaOmics platform. The parties will jointly advance co-development combining Insilico's generative-AI drug discovery capabilities with CMS's R&D and therapeutic expertise. Insilico is eligible to receive up to approximately RMB 1.2 billion (~$165M) in milestone payments plus royalties. Financial split of upfront vs. milestones was not separately disclosed.
The collaboration targets an undisclosed mass-market central nervous system indication via a novel mechanism of action surfaced by AI. CNS disorders remain among the highest-unmet-need, largest-market therapeutic areas, with historically high clinical attrition that AI-driven target discovery aims to reduce.
AI-native drug-discovery peers include Recursion and Isomorphic Labs; CMS brings Chinese commercial and R&D scale. Specific competing programs are undisclosed pending target disclosure.
Second CMS–Insilico pact in ~3 months: co-development of an AI-discovered CNS asset; Insilico eligible for up to ~RMB1.2B (~$165M) in milestones plus royalties.
No disclosed upfront and a preclinical, undisclosed target; upside depends entirely on milestone achievement, but the pact extends a productive CMS–Insilico relationship.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| China Medical System Holdings Limited / Insilico Medicine Inc. (this deal) | 2026 | $165M | 48 |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
← Browse all deals · How we score deals
More: 2026 deals